Dr. Mary Murphy is Senior Lecturer at NUI Galway and a principle investigator at the Regenerative Medicine Institute (REMEDI). Mary’s research interest and motivation is the development of innovative medicines to treat major diseases using mesenchymal stem/stromal cells (MSCs) or MSCs derived from induced pluripotent stem cells and gene therapy to provide new modalities in patient care for osteoarthritis, bone repair and vascular calcification. Current clinical research focuses on the therapeutic potential of MSCs and she is involved in the ADIPOA2 Phase 2 clinical trial to assess adipose-derived stromal cells in osteoarthritis. Basic research is focused on the concept that stem cell depletion, or loss/alteration of function, contributes to the development of chronic degenerative diseases such as osteoarthritis and atherosclerosis, the use of the chondrogenic differentiation pathway of bone marrow-derived MSC as a model to study early changes that occur in osteoarthritis development and the role of inflammation and epigenetics in disease progression. Applied research has a focus on the manufacturing of MSCs for therapeutic use and addresses development of novel fully defined serum/medium for cell growth and scale-up for robotic, economic manufacture. She currently coordinates the H2020-funded AUTOSTEM project to develop a GMP-compliant robotic platform for production of clinical grade MSCs.